Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GMP Carrots For Quality: FDA Considers Incentives To Adopt Quality Systems

Executive Summary

The type of incentive remains under consideration, but one suggestion is a grading system similar to what restaurants receive from local health departments.

You may also be interested in...



Breakthrough Designation Can Be 'Lever' For Manufacturing Evolution, FDA Says

CDER Director Woodcock notes breakthrough program often pushes sponsors to modernize production processes.

FDA Gains Cures Funding In Latest Draft

Additional appropriations would be authorized for drug development tool qualification and manufacturing studies.

FDA’s Plaisier: GMP Oversight Must Shift To Outcomes Model

In an interview with “The Pink Sheet,” the Office of Regulatory Affairs chief says she wants to chart her office’s activities based on their effect on public health instead of simply counting outputs like the number of inspections or 483s.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS054508

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel